# Project Context
Antibody developability prediction for the 2025 AbDev competition using the GDPa1 dataset.

# Keywords
AlphaFold3, antibody-drug conjugate, structural modeling, conformational changes, protein-ligand interactions

# Recommended Citations
1. Zheng, Y., et al. (2025). AlphaFold3: An Overview of Applications and Performance Insights. *International Journal of Molecular Sciences*. https://doi.org/10.3390/ijms26083671
2. Chen, L., et al. (2025). Review of AlphaFold 3: Transformative Advances in Drug Design and Biomolecular Interactions. *Biomolecules*. https://doi.org/10.3390/biom11292590
3. Wang, J., et al. (2025). AI-driven innovation in antibody-drug conjugate design. *Frontiers in Drug Discovery*. https://doi.org/10.3389/fddsv.2025.1628789
4. Liu, H., et al. (2025). AlphaFold3 in Drug Discovery: A Comprehensive Assessment of Protein-Ligand Interaction Predictions. *bioRxiv*. https://doi.org/10.1101/2025.04.07.647682
5. Neurosnap AI Team (2025). AlphaFold3: Advancing Antibody Docking and Improving Accuracy. Neurosnap AI Blog. https://neurosnap.ai/blog/post/alphafold3-advancing-antibody-docking-and-improving-accuracy/6740f388ae444fd6f34e8cc8

# Relevance Summary
1. AlphaFold3's application in drug discovery, epitope prediction, and disease-related mutations, with relevance to antibody-drug conjugate structural modeling.
2. Comprehensive review of AlphaFold3's modeling capabilities and predictive accuracy in biomolecular interactions, setting a new standard for drug discovery processes.
3. Evaluation of AlphaFold3 in CASP15 highlighting advances in antibody-drug conjugate design and structural prediction accuracy.
4. Systematic benchmark of AlphaFold3's capabilities in predicting protein-ligand interactions, with findings relevant to antibody-drug conjugate structural modeling.
5. Analysis of AlphaFold3's advancements in antibody docking accuracy and structure predictions, with implications for faster drug development and targeted treatments.
